We are live on
!
Find out more
FAM
Fred Alger Management Portfolio holdings
AUM
$22.8B
1-Year Est. Return
64.63%
This Fund
S&P 500
This Quarter
Est. Return
+15.81%
1 Year Est. Return
+64.63%
3 Year Est. Return
+243.99%
5 Year Est. Return
+318.3%
10 Year Est. Return
+1,899.64%
AUM
$19.6B
AUM Growth
+$879M
(+4.7%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-6.05%
Top 10 Holdings %
Top 10 Hldgs %
34.09%
Holding
589
New
74
Increased
137
Reduced
233
Closed
78
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$96.2M |
| 2 |
DraftKings
DKNG
|
+$81.7M |
| 3 |
GE HealthCare
GEHC
|
+$81.1M |
| 4 |
GFL Environmental
GFL
|
+$77M |
| 5 |
Vaxcyte
PCVX
|
+$72.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intuit
INTU
|
+$187M |
| 2 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
+$143M |
| 3 |
AbbVie
ABBV
|
+$112M |
| 4 |
Walt Disney
DIS
|
+$99.6M |
| 5 |
HSKA
Heska Corp
HSKA
|
+$80.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 36.16% |
| 2 | Healthcare | 20.31% |
| 3 | Consumer Discretionary | 12.43% |
| 4 | Industrials | 10.17% |
| 5 | Communication Services | 7.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
CAVA Group
CAVA
$7.72B
| $446K | ﹤0.01% |
+10,897
| New | +$449K |
|
|
NUVL
402
DELISTED
Nuvalent
NUVL
| $438K | ﹤0.01% |
10,383
-341
| -3% | -$12.9K |
|
403
Structure Therapeutics
GPCR
$3.37B
| $437K | ﹤0.01% |
+10,512
| New | +$295K |
|
404
C3.ai
AI
$1.38B
| $429K | ﹤0.01% |
+11,787
| New | +$332K |
|
405
Krystal Biotech
KRYS
$10.7B
| $418K | ﹤0.01% |
+3,557
| New | +$363K |
|
406
TechTarget
TTGT
$322M
| $403K | ﹤0.01% |
12,961
-122,264
| -90% | -$4.15M |
|
407
Immunocore
IMCR
$1.69B
| $394K | ﹤0.01% |
6,564
+1,517
| +30% | +$86.6K |
|
408
Allegion
ALLE
$13.4B
| $393K | ﹤0.01% |
3,277
| – | – |
|
409
Super Micro Computer
SMCI
$17.3B
| $393K | ﹤0.01% |
+15,750
| New | +$264K |
|
|
GRCL
410
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $365K | ﹤0.01% |
+95,812
| New | +$268K |
|
411
Voyager Therapeutics
VYGR
$184M
| $365K | ﹤0.01% |
+31,848
| New | +$329K |
|
412
Immunovant
IMVT
$7.89B
| $362K | ﹤0.01% |
19,102
-10,341
| -35% | -$193K |
|
413
PayPal
PYPL
$50.6B
| $357K | ﹤0.01% |
5,345
-611,905
| -99% | -$41.7M |
|
414
Palantir
PLTR
$299B
| $353K | ﹤0.01% |
+23,000
| New | +$261K |
|
415
Pool Corp
POOL
$7.08B
| $349K | ﹤0.01% |
932
| – | – |
|
416
PUT
Carvana
CVNA
$48.4B
| $330K | ﹤0.01% |
+330,000
| New | +$915K |
|
417
Quanterix
QTRX
$160M
| $314K | ﹤0.01% |
+13,935
| New | +$248K |
|
418
Goosehead Insurance
GSHD
$1.66B
| $314K | ﹤0.01% |
4,996
| – | – |
|
419
Pinduoduo
PDD
$126B
| $310K | ﹤0.01% |
+4,487
| New | +$308K |
|
420
Larimar Therapeutics
LRMR
$379M
| $297K | ﹤0.01% |
94,938
-190,797
| -67% | -$778K |
|
|
IMA
421
ImageneBio Inc
IMA
$64.4M
| $271K | ﹤0.01% |
+3,438
| New | +$247K |
|
422
Unity
U
$13.9B
| $233K | ﹤0.01% |
+5,371
| New | +$172K |
|
423
EPAM Systems
EPAM
$5.57B
| $222K | ﹤0.01% |
986
-8,710
| -90% | -$2.19M |
|
424
Atmus Filtration Technologies
ATMU
$4.14B
| $190K | ﹤0.01% |
+8,641
| New | +$181K |
|
425
Jabil
JBL
$30.1B
| $152K | ﹤0.01% |
1,408
+555
| +65% | +$48.9K |
|
Similar funds
CAM
BA
AM
SAM
CHP
Fred Alger Management's Q2 2023 Portfolio in Review
As of Q2 2023, Fred Alger Management held 589 positions worth $19.6B, up 4.7% from $18.7B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Fred Alger Management withdrew a net $1.18B in Q2 2023, closing 78 positions and reducing 233 holdings. Its most notable exit was Prometheus Biosciences, Inc. Common Stock, an estimated $143M position sold in full.
By sector, the portfolio is most concentrated in Technology at 36% of assets, up from 35% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Fred Alger Management opened a new position in DraftKings worth $94.2M.
- Fred Alger Management's largest Q2 2023 buy was DraftKings: 3,544,411 shares worth $94.2M.
- Fred Alger Management added most to Meta Platforms (Facebook) in Q2 2023, an estimated $96.2M increase.
- Fred Alger Management's biggest Q2 2023 reduction was Intuit, cutting an estimated $187M.
- Fred Alger Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $143M.
- Fred Alger Management's ten largest holdings make up 34% of its $19.6B portfolio in Q2 2023.
- Fred Alger Management opened 74 new positions and closed 78 in Q2 2023.
- Fred Alger Management's portfolio value rose 4.7% quarter-over-quarter to $19.6B.
Based on Fred Alger Management's 13F filing for Q2 2023, filed 14 Aug 2023.